In patients suffering from dehydration and renal disease, particularly the elderly, concurrent therapy with other plasma protein binding drugs may necessitate a modification in dosage.
Use in Pregnancy: The safety of mefenamic acid in pregnancy has not been established.
Use in Lactation: Very small amounts enter breast milk and may be transmitted to infants of nursing mothers.
Use in Elderly: Both renal and haematological adverse effects appear to be more prevalent in the elderly. The minimum effective dose should be used and treatment stopped in the presence of diarrhoea or dehydration.